Abstract
Optic pathway gliomas (OPGs) are low-grade neoplasms that may be associated with profound vision loss, endocrinologic deficits, and neurologic dysfunction. OPGs occur sporadically or in association with the neurocutaneous disorder neurofibromatosis type 1 (NF1). There is ample debate regarding the most effective way for ophthalmologists to screen patients with NF1 for the presence of these tumors. Furthermore, the decision to treat and the criteria that serve as a basis for this treatment remain topics of significant discussion amongst the multidisciplinary team managing these patients including pediatric ophthalmologists, neuro-ophthalmologists, neuro-oncologists, neurosurgeons, and geneticists. Prospective natural history data are needed to develop consensus recommendations for a screening protocol for OPGs, the criteria for treatment of OPGs, and risk factors for poor visual outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
